Skip to main content
KOREA PHARMA Co., Ltd. logo

KOREA PHARMA Co., Ltd. — Investor Relations & Filings

Ticker · 032300 ISIN · KR7032300006 KO Manufacturing
Open in API
Filings indexed 178 across all filing types
Latest filing 2021-01-19 Regulatory Filings
Country KR South Korea
Listing KO 032300

About KOREA PHARMA Co., Ltd.

https://www.koreapharma.co.kr/eng/main/…

KOREA PHARMA Co., Ltd. is a pharmaceutical company established in 1974 that specializes in the development and production of prescription-based medicines. The company has a particular focus on drugs for the Central Nervous System (CNS). Its product portfolio covers a wide range of therapeutic areas, including hepatic, gastrointestinal, antimicrobial, and antihistamine drugs. The company also offers treatments such as amino acids, antibiotics, antidotes, and antiepileptics, aiming to improve and maintain public health through its specialized pharmaceutical products.

Recent filings

Filing Released Lang Actions
풍문또는보도에대한해명
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure from a Korean company (Korea Pharma) addressing market rumors regarding their involvement in COVID-19 treatment production. It is a standard 'Clarification of Rumors or Reports' filing, which is a common regulatory requirement in the Korean stock market (KRX). Since it does not fit into specific categories like financial reports, M&A, or dividends, it falls under the general regulatory filing category.
2021-01-19 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the closure of the shareholder register (주주명부폐쇄) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal notice of a corporate action related to shareholder rights and meeting preparation. Given it is a specific regulatory notification that does not fit into the other categories like dividend or share issuance, it is classified as a general regulatory filing.
2020-12-14 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Korea Pharma, covering the period from January 1, 2020, to September 30, 2020. It contains detailed company information, financial data, management discussion, and capital structure details, which are characteristic of a comprehensive interim financial report. It is not a mere announcement or certification, but the full report itself. 9M 2020
2020-11-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of major shareholders and their special relations upon the company's (Korea Pharma) new listing on the KOSDAQ. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-08-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when an executive or major shareholder changes their stake in the company. This falls under the category of 'Director's Dealing' (DIRS), as it reports the personal share transactions/holdings of an executive (Lee Jin-woo, Vice President of Korea Pharma).
2020-08-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal shareholdings and transactions. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2020-08-13 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.